For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according ...
Jul 2, 2026
0
3
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.
Jul 2, 2026
0
6
A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine whether prostate cancers are susceptible to a type of cell death known as ferroptosis. These findings, ...
Jul 2, 2026
0
7
Each additional hour of prolonged, uninterrupted sedentary behavior in a person's day is associated with a 9% higher risk of cancer death, according to a study published in PLOS Medicine by Frederick Ho of the University ...
Jul 2, 2026
0
26
Researchers at Tel Aviv University's Gray Faculty of Medical and Health Sciences have uncovered how a natural and essential immune system process can be hijacked to promote cancer progression. In a new study, the research ...
Jul 2, 2026
0
9
Oral cancer is a major health challenge in India, where tobacco and areca nut use contribute substantially to the disease burden. Despite advances in surgery, chemotherapy and radiotherapy, treatment remains difficult because ...
Jul 2, 2026
0
7
The development of cancer is not a process triggered immediately by the emergence of an oncogenic mutation. There is growing evidence for the existence of an intermediate phase—hitherto poorly defined—in which mutated cells ...
Jul 2, 2026
0
7
Cancer researchers at the Sylvester Firefighter Cancer Initiative (SFCI), part of the University of Miami Miller School of Medicine, took a rare step to better understand the cancer risks wildland firefighters face: They ...
Jul 2, 2026
0
8
Cancer cells are quick to develop resistance to anti-tumor drugs. New research by scientists from the University of California, Davis, shows how cancers adapt to evade a class of anti-tumor drugs called BET inhibitors and ...
Jul 1, 2026
0
6
Researchers at Cima and Clinica Universidad de Navarra have identified new molecular mechanisms underlying multiple myeloma. This type of hematologic cancer, which affects the bone marrow, is characterized by its resistance ...
Jul 1, 2026
0
3
